期刊
JOURNAL OF CELL BIOLOGY
卷 220, 期 8, 页码 -出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1083/jcb.202103090
关键词
-
类别
资金
- Instituto de Salud Carlos III [PI16/01224]
- Ministerio de Ciencia e Innovacion [RTC2019-007067-1]
- Generalitat de Catalunya [AGAUR 2017 SGR 537]
- EDIReX [H2020 INFRAIA 731105-2]
- Canadian Institutes of Health Research [PJT-159767]
- FERO foundation
The oncogene Myc, deregulated in the majority of human tumors, has been a challenging target for drug development due to its disordered nature and lack of binding pocket. Recent breakthroughs have led to the development of Myc inhibitors, with a direct inhibitor currently in clinical trials, marking a significant milestone in the effort to target this previously undrugged gene.
The oncogene Myc is deregulated in the majority of human tumors and drives numerous hallmarks of cancer. Despite its indisputable role in cancer development and maintenance, Myc is still undrugged. Developing a clinical inhibitor for Myc has been particularly challenging owing to its intrinsically disordered nature and lack of a binding pocket, coupled with concerns regarding potentially deleterious side effects in normal proliferating tissues. However, major breakthroughs in the development of Myc inhibitors have arisen in the last couple of years. Notably, the direct Myc inhibitor that we developed has just entered clinical trials. Celebrating this milestone, with this Perspective, we pay homage to the different strategies developed so far against Myc and all of the researchers focused on developing treatments for a target long deemed undruggable.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据